GUMDROP : CUA - A Phase 2 multi-center prospective open label 2-dose level clinical safety and efficacy evaluation of injection of NX-1207 for the treatment of low risk, localized (T1c) Prostate Cancer.

Created by Nancy Dawson, last modified on Jun 01, 2013
Description:This study is designed to evaluate the safety and efficacy of a single injection of NX-1207 for the treatment of biopsy-confirmed low risk localized (T1c) prostate cancer in patients currently undergoing active surveillance.
Link:http://clinicaltrials.gov/ct2/show/study/NCT01620515
Site:Chesapeake Urology Associates
Principal Investigator: Please contact Nymox at 800-936-9669